Sign in to fuzzto save your conversations, follow your research and come back anytime.

Aarti Industries Limited is an Indian company specializing in benzene-based specialty chemicals and intermediates. It operates in two segments: Specialty Chemicals and Pharmaceuticals. The company serves various industries including polymers, agrochemicals, dyes, pigments, pharmaceuticals, and fuel additives. Aarti Industries has a global presence, exporting to over 60 countries and ranking between 1st and 4th globally for 75% of its specialty chemical portfolio. The company has three R&D centers and multiple manufacturing facilities across India. It produces over 200 products and serves more than 700 domestic and 300 export customers. Aarti Industries has undergone significant expansion over the years, increasing production capacities and acquiring new technologies. The company has also entered into long-term supply contracts with global chemical and agricultural companies, demonstrating its strong market position.
In the news

Aarti Industries, Jio Financial among top picks for Aug 13

Aarti Industries Q1 profit surges 260% to ₹155 crore, stock gains 2.20%

Stocks to buy: Angel One analyst recommends Aarti Industries, ICICI Prudential

KEI Industries gets 'Accumulate' rating from Prabhudas Lilladher

Aarti Industries invests ₹200-250 cr in Dahej backward integration

Aarti Industries Q3 net profit surges 189% to ₹133 crore
The Quarter story
The two most recent quarterly results, compared side-by-side.
Aarti Industries delivers strong revenue and profit growth as most plants run at higher capacity, while a few segments face demand softening.
Revenue grew from ₹1,867 Cr in Q1 FY26 to ₹2,627 Cr in Q1 FY27, showing consistent top-line expansion.
PDA capacity utilization fell from 67% in Q1 FY26 to 43% in Q3 FY26, signaling weakening operational demand.
PAT jumped from ₹43 Cr in Q1 FY26 to ₹155 Cr in Q1 FY27, highlighting strong profit recovery.
PDA production volume declined from 2.0 kT in Q1 FY26 to 1.5 kT in Q4 FY26, reflecting weak segment demand.
MMA capacity utilization surged from 60% in Q1 FY26 to 96% in Q3 FY26, reflecting robust plant demand.
Polymer & Additives revenue share dropped from 14% in Q1 FY26 to 11% in Q1 FY27, indicating slight segment softening.
Pharmaceuticals revenue share recovered from 12% in Q1 FY26 to 14% in Q1 FY27, signaling segment resurgence.
Energy & Additives revenue share moderated from 36% in Q1 FY26 to 38% in Q1 FY27 after peaking at 51%, reflecting normalized demand cycles.
DCB production volume rose from 19.3 kT in Q1 FY26 to 29.3 kT in Q4 FY26, indicating sustained output growth.